Ping Gao
Research Subjects
Ping Gao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Bin Chen
Laboratory of Medical Biomaterials Tianjin Institute of Medical & Pharmaceutical Sciences Tianjin China
2 shared publicationsXiaohui Wang
Laboratory of Traditional Chinese Medicine Preparations Tianjin Institute of Medical & Pharmaceutical Sciences Tianjin China
2 shared publicationsMengrou Shi
Tianjin Institute of Medical & Pharmaceutical Sciences
1 shared publicationRui Zhang
School of Pharmaceutical Science and Technology Tianjin University Tianjin China
1 shared publicationTing Zhang
Tianjin Institute of Medical & Pharmaceutical Sciences
1 shared publication- Ting Zhang
Cardiovascular and Cerebrovascular Drugs Research and Development Center, Tianjin Institute of Medical and Pharmaceutical Sciences, Tianjin, 300020, China
1 shared publication
Latest Publications
- 23 August 2023
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 38 (1) , 139-151
Preliminary evaluation of the efficacy and safety of brimonidine for deep sedation
Background: Although brimonidine is currently used in the clinical treatment of glaucoma and rosacea, research of the deep sedative effect on animals after systemic administration is reported firstly and has shown promising results. Methods: The median effective dose (ED50), the median lethal dose (LD50), and the therapeutic index of brimonidine for deep sedation and formalin stimulation assay were determined by various animal experiments. The effect of synergistic anesthesia in rabbits with brimonidine and chloral hydrate was preliminarily evaluated. Results: The ED50 of brimonidine for highly effective sedation by intraperitoneal injection in rats was calculated to be 2.05 mg kg(-1) with a 95% confidence interval (CI) of 1.87 to 2.25 mg kg(-1). The ED50 of brimonidine for deep sedation by intravenous and intrarectal injection in rabbits was calculated to be 0.087 mg kg(-1) with a 95% CI of 0.084 to 0.091 mg kg(-1) and 1.65 mg kg(-1) with a 95% CI of 1.43 to 1.91 mg kg(-1), respectively. The LD50 of intraperitoneal brimonidine injection in rats was calculated to be 468 mg kg(-1) with a 95% CI of 441 to 497 mg kg(-1) and a therapeutic index of 228. Brimonidine has a certain analgesic and heart rate lowering effects. Conclusion: The results confirmed that brimonidine has deep sedation and analgesic effects after systemic administration and has high safety. It can be used in combination with other types of sedative drugs to achieve better effects.
- 23 August 2023
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 38 (1) , 139-151
Preliminary evaluation of the efficacy and safety of brimonidine for deep sedation
Background: Although brimonidine is currently used in the clinical treatment of glaucoma and rosacea, research of the deep sedative effect on animals after systemic administration is reported firstly and has shown promising results. Methods: The median effective dose (ED50), the median lethal dose (LD50), and the therapeutic index of brimonidine for deep sedation and formalin stimulation assay were determined by various animal experiments. The effect of synergistic anesthesia in rabbits with brimonidine and chloral hydrate was preliminarily evaluated. Results: The ED50 of brimonidine for highly effective sedation by intraperitoneal injection in rats was calculated to be 2.05 mg kg(-1) with a 95% confidence interval (CI) of 1.87 to 2.25 mg kg(-1). The ED50 of brimonidine for deep sedation by intravenous and intrarectal injection in rabbits was calculated to be 0.087 mg kg(-1) with a 95% CI of 0.084 to 0.091 mg kg(-1) and 1.65 mg kg(-1) with a 95% CI of 1.43 to 1.91 mg kg(-1), respectively. The LD50 of intraperitoneal brimonidine injection in rats was calculated to be 468 mg kg(-1) with a 95% CI of 441 to 497 mg kg(-1) and a therapeutic index of 228. Brimonidine has a certain analgesic and heart rate lowering effects. Conclusion: The results confirmed that brimonidine has deep sedation and analgesic effects after systemic administration and has high safety. It can be used in combination with other types of sedative drugs to achieve better effects.
- Open Access
- 26 August 2021
- Published by Springer Nature in Research Square
Preliminary Evaluation of the Efficacy and Safety of Brimonidine for General Anesthesia
Background:To determine the hypnotic and analgesic effects of brimonidine, and evaluate its efficacy and safety for general anesthesia. Potentiation of pentobarbital sleeping time with brimonidine was observed in mice, as was analgesic activity of brimonidine.Methods:The median effective dose (ED50)and lethal dose (LD50) of intraperitoneally injected brimonidine were determined in hypnotized mice. In addition, LD50 of intravenously injected brimonidine, ED50 of intravenously , intramuscularly and intrarectally injected brimonidine in hypnotized rabbits were determined. The synergistic anesthetic effect of brimonidine and chloral hydrate on rabbits was evaluated. Results:Intraperitoneal injection of 10 mg/kg brimonidine enhanced the hypnotic effect of a threshold dose of pentobarbital. Intraperitoneal injection brimonidine produced dose-related analgesic effects in mice. ED50 of intraperitoneally administered brimonidine in hypnotized mice was 75.7 mg/kg, and LD50 was 379 mg/kg. The ED50 of intravenous, intramuscular and intrarectal brimonidine for hypnosis in rabbits were 5.2 mg/kg, 8.8 mg/kg and 8.7mg/kg, respectively, and LD50 of intravenous brimonidine was 146 mg/kg. Combined intravenous administration of 0.6 mg/kg brimonidine and 0.03 g/kg chloral hydrate had a synergistic anesthetic effects.Conclusions:Brimonidine elicited hypnotic and analgesic effects after systemic administration, and exhibited safety. Brimonidine enhanced the effects of other types of narcotics when combined.
- 26 August 2021
- Published by Springer Nature in Research Square
Open AccessPreliminary Evaluation of the Efficacy and Safety of Brimonidine for General Anesthesia
Background:To determine the hypnotic and analgesic effects of brimonidine, and evaluate its efficacy and safety for general anesthesia. Potentiation of pentobarbital sleeping time with brimonidine was observed in mice, as was analgesic activity of brimonidine.Methods:The median effective dose (ED50)and lethal dose (LD50) of intraperitoneally injected brimonidine were determined in hypnotized mice. In addition, LD50 of intravenously injected brimonidine, ED50 of intravenously , intramuscularly and intrarectally injected brimonidine in hypnotized rabbits were determined. The synergistic anesthetic effect of brimonidine and chloral hydrate on rabbits was evaluated. Results:Intraperitoneal injection of 10 mg/kg brimonidine enhanced the hypnotic effect of a threshold dose of pentobarbital. Intraperitoneal injection brimonidine produced dose-related analgesic effects in mice. ED50 of intraperitoneally administered brimonidine in hypnotized mice was 75.7 mg/kg, and LD50 was 379 mg/kg. The ED50 of intravenous, intramuscular and intrarectal brimonidine for hypnosis in rabbits were 5.2 mg/kg, 8.8 mg/kg and 8.7mg/kg, respectively, and LD50 of intravenous brimonidine was 146 mg/kg. Combined intravenous administration of 0.6 mg/kg brimonidine and 0.03 g/kg chloral hydrate had a synergistic anesthetic effects.Conclusions:Brimonidine elicited hypnotic and analgesic effects after systemic administration, and exhibited safety. Brimonidine enhanced the effects of other types of narcotics when combined.